Sensitization of Non-Small Cell Lung Cancer Cells to Gefitinib and Reversal of Epithelial-Mesenchymal Transition by Aloe-Emodin PI3K/Akt/TWIS1 Signal Blockage

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Jun 9

PMID 35677158

Authors

Minghui Peng

Zhuifeng Zheng

Shaoyang Chen

Le Fang

Rongxiu Feng

Lijun Zhang

Qingnan Tang

Xuewen Liu

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the impacts of AE (aloe-emodin) in gefitinib-resistant NSCLC (non-small cell lung cancer) cells and the corresponding mechanism.

Methods: PC9 and PC9-GR cells were cultured and treated by gefitinib, AE, or the combination of the two drugs. Then, viability, apoptosis, migration and invasion of cells were investigated using CCK-8, TUNEL, wound healing assay, and transwell assay, respectively. Female BALB/c nude mice were employed for the establishment of xenograft tumor models to examine the role of AE in tumor growth.

Results: PC9-GR cells showed reduced apoptosis and enhanced cell viability, migration and invasion upon treatment by gefitinib, compared with PC9 cells. E-cahherin in PC9-GR cells was down-regulated, while Vimentin, Snail2 (or Slug) and Twist1 in PC9-GR cells were up-regulated, compared with PC9 cells. Meanwhile, treatment by a combination of gefitinib and AE significantly strengthened apoptosis of PC9-GR cells, while attenuated their migration and invasion, compared with the control group or treatment by gefitinib or AE alone. WB results showed that AE could reverse EMT and activation of PI3K/AKT signalling pathway in PC9-GR cells. experiments showed that tumor growth and EMT of PC9-GR cells were dramatically repressed after treatment by a combination of AE and gefitinib. Additionally, the use of SC97 (a PI3K/Akt pathway activator) could counteract the effects of AE in gefitinib-resistant PC9 cells.

Conclusions: AE could enhance the gefitinib sensitivity of PC9-GR cells and reverse EMT by blocking PI3K/Akt/TWIS1 signal pathway.

Citing Articles

Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical applications.

Hashemi M, Abolghasemi Fard A, Pakshad B, Asheghabadi P, Hosseinkhani A, Hosseini A Noncoding RNA Res. 2024; 11:1-21.

PMID: 39720352 PMC: 11665378. DOI: 10.1016/j.ncrna.2024.11.006.

Unveiling Anthraquinones: Diverse Health Benefits of an Essential Secondary Metabolite.

Khatoon M, Dubey A, Janhvi K, Km Verma J Recent Pat Biotechnol. 2024; 19(3):179-197.

PMID: 38967073 DOI: 10.2174/0118722083301761240628083511.

Aloe-emodin: Progress in Pharmacological Activity, Safety, and Pharmaceutical Formulation Applications.

Luo H, Ji X, Zhang M, Ren Y, Tan R, Jiang H Mini Rev Med Chem. 2024; 24(19):1784-1798.

PMID: 38639277 DOI: 10.2174/0113895575298364240409064833.

Shake It Up Baby Now: The Changing Focus on TWIST1 and Epithelial to Mesenchymal Transition in Cancer and Other Diseases.

Mirjat D, Kashif M, Roberts C Int J Mol Sci. 2023; 24(24).

PMID: 38139368 PMC: 10743446. DOI: 10.3390/ijms242417539.

An N6-methyladenosine regulation- and mRNAsi-related prognostic index reveals the distinct immune microenvironment and immunotherapy responses in lower-grade glioma.

Tang G, Peng J, Huo L, Yin W BMC Bioinformatics. 2023; 24(1):225.

PMID: 37264314 PMC: 10236841. DOI: 10.1186/s12859-023-05328-7.

References

Moammeri A, Abbaspour K, Zafarian A, Jamshidifar E, Motasadizadeh H, Dabbagh Moghaddam F . pH-Responsive, Adorned Nanoniosomes for Codelivery of Cisplatin and Epirubicin: Synergistic Treatment of Breast Cancer. ACS Appl Bio Mater. 2022; 5(2):675-690. PMC: 8864616. DOI: 10.1021/acsabm.1c01107. View

Sanders B, Ray A, Goldberg S, Clark T, McDaniel H, Atlas S . Anti-cancer effects of aloe-emodin: a systematic review. J Clin Transl Res. 2019; 3(3):283-296. PMC: 6426255. View

Makvandi P, Chen M, Sartorius R, Zarrabi A, Ashrafizadeh M, Dabbagh Moghaddam F . Endocytosis of abiotic nanomaterials and nanobiovectors: Inhibition of membrane trafficking. Nano Today. 2021; 40:101279. PMC: 8425779. DOI: 10.1016/j.nantod.2021.101279. View

Chen Y, Liu P, Shen D, Liu H, Xu L, Wang J . FAM172A inhibits EMT in pancreatic cancer via ERK-MAPK signaling. Biol Open. 2020; 9(2). PMC: 7044457. DOI: 10.1242/bio.048462. View

Terlizzi M, Colarusso C, Pinto A, Sorrentino R . Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness. Pharmacol Ther. 2019; 202:140-148. DOI: 10.1016/j.pharmthera.2019.06.005. View

Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z . PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020; 11(9):797. PMC: 7515865. DOI: 10.1038/s41419-020-02998-6. View

Singh A, Settleman J . EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29(34):4741-51. PMC: 3176718. DOI: 10.1038/onc.2010.215. View

Wang J, Zhang Z, Li R, Mao F, Sun W, Chen J . ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR/ERK signaling pathway. Biomed Pharmacother. 2017; 97:1066-1077. DOI: 10.1016/j.biopha.2017.11.034. View

Ma J, Hung C, Lin Y, Ho C, Kao J, Way T . Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells. Oncotarget. 2016; 7(37):58915-58930. PMC: 5312285. DOI: 10.18632/oncotarget.10410. View

10.

Xu E, Xia X, Jiang C, Li Z, Yang Z, Zheng C . GPER1 Silencing Suppresses the Proliferation, Migration, and Invasion of Gastric Cancer Cells by Inhibiting PI3K/AKT-Mediated EMT. Front Cell Dev Biol. 2021; 8:591239. PMC: 7793665. DOI: 10.3389/fcell.2020.591239. View

11.

Cheng G, Pi Z, Zhuang X, Zheng Z, Liu S, Liu Z . The effects and mechanisms of aloe-emodin on reversing adriamycin-induced resistance of MCF-7/ADR cells. Phytother Res. 2021; 35(7):3886-3897. DOI: 10.1002/ptr.7096. View

12.

Dou F, Liu Y, Liu L, Wang J, Sun T, Mu F . Aloe-Emodin Ameliorates Renal Fibrosis Via Inhibiting PI3K/Akt/mTOR Signaling Pathway and . Rejuvenation Res. 2018; 22(3):218-229. DOI: 10.1089/rej.2018.2104. View

13.

Wen L, Zhang X, Zhang J, Chen S, Ma Y, Hu J . Paxillin knockdown suppresses metastasis and epithelial‑mesenchymal transition in colorectal cancer via the ERK signalling pathway. Oncol Rep. 2020; 44(3):1105-1115. PMC: 7388420. DOI: 10.3892/or.2020.7687. View

14.

Wang K, Ji W, Yu Y, Li Z, Niu X, Xia W . FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer. Oncogene. 2018; 37(39):5340-5354. DOI: 10.1038/s41388-018-0311-3. View

15.

Zhu X, Chen L, Liu L, Niu X . EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies. Front Oncol. 2019; 9:1044. PMC: 6798878. DOI: 10.3389/fonc.2019.01044. View

16.

Aleksakhina S, Kashyap A, Imyanitov E . Mechanisms of acquired tumor drug resistance. Biochim Biophys Acta Rev Cancer. 2019; 1872(2):188310. DOI: 10.1016/j.bbcan.2019.188310. View

17.

Erin N, Grahovac J, Brozovic A, Efferth T . Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020; 53:100715. DOI: 10.1016/j.drup.2020.100715. View

18.

Shibue T, Weinberg R . EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017; 14(10):611-629. PMC: 5720366. DOI: 10.1038/nrclinonc.2017.44. View

19.

Gooding A, Schiemann W . Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance. Mol Cancer Res. 2020; 18(9):1257-1270. PMC: 7483945. DOI: 10.1158/1541-7786.MCR-20-0067. View

20.

Farani M, Azarian M, Hossein H, Abdolvahabi Z, Abgarmi Z, Moradi A . Folic Acid-Adorned Curcumin-Loaded Iron Oxide Nanoparticles for Cervical Cancer. ACS Appl Bio Mater. 2022; 5(3):1305-1318. PMC: 8941513. DOI: 10.1021/acsabm.1c01311. View